Why Accelerate Diagnostics (AXDX) Stock Is Down 38%

Zinger Key Points
  • Accelerate Diagnostics shares are trading lower by 38% during Friday's session.
  • The company priced an underwritten public offering of 6,860,659 units at $1.50 each.

Accelerate Diagnostics, Inc. AXDX shares are trading lower by 38% to $1.00 during Friday’s session after the company priced an underwritten public offering of 6,860,659 units at $1.50 each, comprising a share of common stock and a warrant.

What Else?

The underwriters have an option for an additional 1,029,098 shares and/or warrants. Warrants are exercisable at $1.65 per share, pre-funded warrants at $0.01 per share, both valid for five years. Gross proceeds are expected to be $10.3 million.

Concurrently, a private placement to the Jack W. Schuler Living Trust involves the sale of 1,156,069 units at $1.73 per unit, with an agreement for an additional 1,560,693 units. Gross proceeds from the private placement are expected to be $4.7 million.

The public offering is set to close around January 23, subject to customary conditions. William Blair & Company, L.L.C. is the sole book-running manager, and Craig-Hallum Capital Group LLC is the co-manager.

See Also: Fed's Goolsbee Expects Interest Rates To Fall With Inflation

According to data from Benzinga Pro, AXDX has a 52-week high of $11.90 and a 52-week low of $0.95.

Market News and Data brought to you by Benzinga APIs
Posted In: Newswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...